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Aims Thiazolidinediones are insulin sensitizers, and are associated with fluid retention and increased risk of heart failure (HF) in
people with type 2 diabetes. We assessed fatal and non-fatal HF events and their outcome, and identified HF predictors in
the RECORD (Rosiglitazone Evaluated for Cardiac Outcomes and Regulation of glycaemia in Diabetes) trial population.
Methods and
results
In a multicentre, open-label study, we randomized 4447 people with type 2 diabetes on metformin or sulfonylurea mono-
therapy with a mean HbA1c of 7.9% to add-on rosiglitazone (n ¼ 2220) or to a combination of metformin and sulfonylurea
(n ¼ 2227) and followed them over 5.5 years on average. Heart failure hospitalizations and deaths were adjudicated by a
Clinical Endpoint Committee using pre-specified criteria. Independent predictors of HF events were identified out of a
group of 30 pre-specified clinical, demographic, and biological variables. In the rosiglitazone group, the risk of HF death
or hospitalization was doubled: HR¼ 2.10 (95% CI, 1.35–3.27): the excess HF event rate was 2.6 (1.1–4.1) per 1000
person-years. An excess in HF deaths was observed (10 vs. two), including four HF deaths as first HF events. By contrast,
there was no increase in cardiovascular mortality or hospitalization (HR ¼ 0.99, 95% CI, 0.85–1.16) or in cardiovascular
deaths (60 vs. 71). Independent predictors of HF were rosiglitazone assignment, age, urinary albumin : creatinine ratio,
body mass index, and systolic blood pressure at baseline. A history of previous cardiovascular disease was not predictive
of HF. Duration of HF hospitalization and rate of HF re-hospitalization were similar in the two groups.
Conclusion These findings confirm the increased risk of HF events in people treated with rosiglitazone and support the recommen-
dation that this agent should not continue to be used in people developing symptomatic HF while using the medication.
Close follow-up for the risk of HF should be offered to elderly people, people with markedly increased body mass index,
people with microalbuminuria/proteinuria, and people with increased systolic blood pressure.
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Introduction
Thiazolidinediones (TZDs) are peroxisome proliferator-activated
receptor (PPARg) agonists that improve insulin sensitivity in the
liver, adipose tissue, and skeletal muscle, thus improving glycaemic
control. In 2000, rosiglitazone and pioglitazone received marketing
authorization for use in combination with metformin or sulfony-
lurea in type 2 diabetes in Europe. Although it was recognized
that TZDs caused fluid retention, the suggestion that these
agents might precipitate or aggravate heart failure (HF) was
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more controversial. International guidelines advised against the use
of TZDs in patients with New York Heart Association class III and
IV HF, but accepted cautious use in those with less severe symp-
toms or asymptomatic structural heart disease.1– 4 Subsequently,
the PROactive study, which enrolled type 2 diabetes patients
with macrovascular disease, showed that the incidence of HF
was increased by 30% with pioglitazone.5
A recent meta-analysis including more than 20 000 patients
treated with TZDs showed an increased risk of HF events of
72% and suggested that this risk was a class effect of TZDs.6
Observational studies have also confirmed that HF events are
increased in elderly diabetic patients treated with TZDs.7
However, these findings have to be treated with caution as HF
was generally an investigator-reported outcome, with the
concern that fluid retention and oedema may have been
misdiagnosed.
RECORD (Rosiglitazone Evaluated for Cardiac Outcomes and
Regulation of glycaemia in Diabetes) showed that rosiglitazone in
combination therapy did not increase the risk of overall cardiovas-
cular mortality or of morbidity compared with a combination of
metformin and sulfonylurea.8
Here, we report a detailed analysis of HF events in the RECORD
trial which accumulated around 25 000 person-years of follow-up
and provides the opportunity to address the issue of HF in a
large population with an adjudication based on predefined criteria
performed by a Clinical Endpoint Committee (CEC) the members
of which were blind to treatment allocation. Fatal and non-fatal
outcomes following HF hospitalization were also determined.
Methods
Study design and conduct
RECORD was a prospective randomized, multicentre clinical trial of
dual therapy in type 2 diabetes, comparing rosiglitazone plus either
metformin or a sulfonylurea with metformin plus sulfonylurea, as the
active control arm. It is registered on www.clinicaltrials.gov as
NCT00379769.
The study design has been described in detail previously.9 Briefly,
people with type 2 diabetes on monotherapy with either metformin
or sulfonylurea and in less than optimal blood glucose control
(HbA1c . 7.0–9.0%) were randomized to receive in an open-label
design addition of rosiglitazone or metformin (if already on sulfony-
lurea) or of rosiglitazone or sulfonylurea (if already on metformin).
The study had an open-label design, and its aim was to assess the non-
inferiority of rosiglitazone combination to metformin/sulfonylurea for
cardiovascular outcomes, the primary endpoint being the time to
first cardiovascular hospitalization or cardiovascular death including
HF. Data on glucose control and ambulatory blood pressure have
been published.10,11, The study was conducted in 364 centres in 25
countries in Europe and Australasia.
Randomization was by telephone from a dedicated centre, using
random-permuted blocks stratified by background medication. The
study was not blinded because of planned differences in the strategy
for rescue therapy (see below), and the need to allow different
types and doses of comparator sulfonylurea therapy. Choice of sulfo-
nylurea from glimepiride, gliclazide, or glibenclamide (glyburide) was
according to local investigator practice. Other glucose-lowering thera-
pies were not permitted.
Patients
We recruited patients for the study from April 2001 through April
2003. Eligible patients had type 2 diabetes, as defined by criteria of
the World Health Organization, were between the ages of 40 and
75 years, had a body mass index (weight in kilograms divided by the
square of height in metres) of .25.0 kg/m2, and had a glycated haemo-
globin level of .7.0% and 9.0% while receiving maximum doses of
metformin or a sulfonylurea. Exclusion criteria were the current use
of other glucose-lowering agents, hospitalization for a major cardiovas-
cular event in the previous 3 months, a planned cardiovascular inter-
vention, HF, clinically significant hepatic disease, renal impairment,
and uncontrolled hypertension. The study protocol was approved by
ethics committees or institutional review boards in accordance with
the laws and customs of each country participating in the study.
Written informed consent was obtained from all patients.
Oral glucose-lowering medications
Oral therapies were managed throughout to a target HbA1c of 7.0%.
Rosiglitazone (Avandia, GlaxoSmithKline, UK) was begun at 4 mg/day,
and titrated to 8 mg/day any time after 8 weeks of therapy if not to
target. The starting dose of metformin and sulfonylurea varied by
local practice, with dose increases permitted from 8 weeks.
Maximum daily dose of 2550 mg metformin, 15 mg glibenclamide (or
equivalent for different preparations), 240 mg gliclazide, or 4 mg glime-
piride were stipulated. The criterion for ‘rescue’ therapy by the
addition of the third oral agent (if in the rosiglitazone arm) was a con-
firmed HbA1c of 8.5%. Subsequently, if participants taking triple
therapy, including rosiglitazone, had a confirmed HbA1c 8.5%, rosigli-
tazone was to be stopped and insulin therapy substituted.
Heart failure events
Deaths and investigator-identified cardiovascular events were ident-
ified through adverse event reporting and/or direct questioning at
study visits using trial record forms. Data from all relevant clinical
sources were collected by a clinical trials organization (Quintiles,
Bracknell, UK) and provided to an independent CEC the members
of which were blind to treatment allocation. This Committee com-
prised five cardiologists, one diabetologist, and one stroke specialist
(see Appendix 1). All events were randomly allocated to a pair of
members of the CEC. In case of disagreement, events were discussed
by the full committee.
Heart failure diagnosis required the presence of typical signs and
symptoms of HF plus objective evidence of cardiac dysfunction plus
objective change in HF medications. Heart failure death and hospitaliz-
ation were defined as death/hospitalization due to the onset and pro-
gression of symptoms defining definite HF as described above. Change
in current HF medication was defined by an increase in dose or IV
medication or introduction of a new class of medication specific for
the treatment of HF.
Statistical analysis
Statistical methods used for the sample size calculation and the end-
point analysis for the RECORD study have been reported previously.8
The analysis was performed on an intention-to-treat basis and included
all patients who were randomized and treated. A sensitivity ‘per-
protocol’ analysis was conducted restricted to each participant’s
time on dual-combination therapy plus 30 days thereafter. The (unad-
justed) incidence of HF (fatal and non-fatal) was analysed by fitting a
Cox proportional hazards regression stratified for background medi-
cation and using time from randomization to the first event of HF.
The comparison between the rosiglitazone group and the active
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control group was estimated as a hazard ratio (HR) with 95% CI and a
two-sided P-value derived from an asymptotic Wald test.
Multivariable regression analysis was used to identify factors predic-
tive of HF (fatal and non-fatal). Variable selection was carried out using
a stepwise selection algorithm at the significance level of 5%. This
analysis considered 30 baseline characteristics identified a priori by
the steering committee (see Appendix 2), along with randomized
study treatment. The multivariable analysis was based on the subset
of patients who had complete data available on these variables. The
statistical contribution of each variable to the prediction of outcome
was assessed by the x2 statistic.
To evaluate the potential effects of related variables on the findings,
the modelling was repeated combining some variables based on clinical
judgement: myocardial infarction, other ischaemic heart disease (IHD)
items, peripheral vascular disease, and cerebrovascular disease were
pooled into prior cardiovascular disease; medical history of hyperten-
sion, systolic blood pressure .130 mmHg, and diastolic blood
pressure .80 mmHg were pooled into hypertension; variables
related to any lipid disorder, to the use of diuretics, and to the use
of antihypertensive therapy were also combined. The model adjusted
for the effects of rosiglitazone assignment, age, gender, and years from
the first diagnosis of diabetes.
Simple descriptive summaries and figures were otherwise used to
compare the two treatment groups.
The statistical analysis was done by the sponsor’s statistician accord-
ing to predefined agreement by the steering committee, with SAS soft-
ware version 8.2 (Cary, NC, USA).
Results
Participants
The design of the study is shown in Figure 1. In the study, 2222
people on metformin were assigned to additional rosiglitazone
(1117) or sulfonylurea (1105) and 2225 patients on sulfonylurea
were assigned to additional rosiglitazone (1103) or metformin
(1122). Mean follow-up was 5.5 years, which corresponded to
12 338 person-years in the rosiglitazone group and 12 272 person-
years in the comparator group. In the rosiglitazone group, 75% of
person-years follow-up were on dual oral therapy and 13% on
triple oral therapy (88% in total). In the control group, 83% of
person-years follow-up were on dual oral therapy. While 61%
(rosiglitazone) and 51% (control group) of participants completed
the study to the final visit on randomized treatment, the pro-
portion of person-time exposed to randomized treatment is a
more relevant indicator of time on study drug (88% rosiglitazone,
83% control).
A significant increase in the use of cardiovascular medications
was observed during the course of the trial. In particular, there
was more use of loop diuretic agents in the rosiglitazone group
at 5 years (11.3 and 7.2% on rosiglitazone and active control,
respectively).
The primary outcome of the first occurrence of cardiovascular
mortality or hospitalization has been published elsewhere, and
showed that rosiglitazone in combination therapy was not inferior
to standard combination therapy with metformin and
sulfonylurea.8
The incidence of HF events (either fatal or non fatal) was
approximately doubled: 61 cases were observed in the rosiglita-
zone group vs. 29 in the active control group (HR ¼ 2.10, 95%
CI 1.35–3.27), P ¼ 0.0010. The estimated excess event rate for
HF was 2.6 (1.1–4.1) per 1000 person-years. Figure 2A shows
the Kaplan–Meier curve for HF events in the intention-to-treat
analysis. The curves started to diverge early and continued to
diverge during the whole course of the trial. Of the 61 patients
with either fatal or non-fatal HF on rosiglitazone, the first event
was non-fatal in 57 patients. In the active control group, the first
HF event was non-fatal in all 29 patients (36 HF hospitalizations).
A ‘per-protocol’ analysis censoring any participant 30 days after
transfer from dual therapy gave similar results [HR 1.91 (95% CI,
1.15–3.19), P ¼ 0.013], 40 people with HF events on rosiglitazone
vs. 23 on active control, with exposures of 9310 and 10 236
person-years, respectively. Figure 2B shows the Kaplan–Meier
curves for the per-protocol analysis.
The mean duration of admission for HF hospitalization (69
events in the Rosiglitazone group, 36 in the active control group)
was similar in the two groups [10.5+6.6 days (SD) in the rosigli-
tazone group vs. 9.6+ 5.3 days (SD) in the control group].
Post-admission outcome in patients who developed a first HF
event is shown in Table 1. Ten people in the rosiglitazone group
died of HF vs. two in the active control group. Four of these
events were the first HF event and another six events occurred
after the occurrence of the first HF event. Seventeen (30%) of
the 57 patients who survived a first HF episode died subsequently
in the rosiglitazone group including six HF deaths when compared
with 8/29 patients (28%) in the control group with two additional
HF deaths. Seven further non-fatal HF events (12%) were observed
in the rosiglitazone group when compared with five (17%) in the
control group.
There were more first HF events in the rosiglitazone group
compared with the active control group, although a similar pro-
portion of patients had recurrent episodes of HF in the both
groups (12/57 vs. 6/29).
Forty-five of the 57 people in the rosiglitazone group who sur-
vived the first non-fatal HF event were still taking rosiglitazone at
the time of the event. Nineteen had rosiglitazone discontinued
and 26 were maintained on rosiglitazone.
The risk of HF was assessed in people with/without a history of
IHD. Table 2 shows that the relative increase in risk was similar in
Figure 1 Study design of the RECORD trial.
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the two subgroups (interaction P ¼ 1.00), but the absolute risk of
HF events was doubled for both the rosiglitazone and the active
control group in the IHD patients.
Table 3 compares the baseline characteristics of patients who
developed HF over time vs. those without HF events.
A modelling analysis of predictors of HF events was performed
using 30 demographic, clinical, and biological baseline character-
istics. Table 4 shows the independent predictors of HF that were
identified through the modelling analysis: assignment to rosiglita-
zone, increased age, increased BMI, urinary albumin : creatinine
ratio (microalbuminuria/proteinuria), and increased systolic blood
pressure. A history of myocardial infarction, peripheral vascular
disease, or diagnosed hypertension were not identified as predic-
tors in the stepwise regression. However, interpretation is
limited by the relatively low number of HF events in the study
and by the small proportion of people within some of the
factors investigated, such as myocardial infarction.
In the modelling analysis combining some variables by clinical
judgement, four variables were identified as significant predictors
(in addition to assignment to rosiglitazone and age already in the
model): body mass index, urinary albumin : creatinine ratio (micro-
albuminuria/proteinuria), antihypertensive drug use, and
Figure 2 Kaplan–Meier plots of time to heart failure (fatal or non-fatal) in the RECORD study (yellow, rosiglitazone group, blue, active
control group). (A) Intent-to-treat analysis and (B) per-protocol þ30 days analysis.
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uncontrolled hypertension at baseline, whereas a previous cardio-
vascular disease was not predictive (P ¼ 0.070 in the final model of
stepwise regression).
Within this further analysis, the HRs (95% CI) were: 1.10 (1.07–
1.13) for age per 1-year increase; 2.95 (1.90–4.57) for the pres-
ence of microalbuminuria/proteinuria vs. normoalbuminuria; 1.11
(1.06–1.15) for body mass index per 1 kg/m2 increase; 2.34
(1.47–3.72) for rosiglitazone assignment vs. control; 2.74 (1.40–
5.36) for baseline antihypertensive therapy yes vs. no; 1.66
(1.06–2.62) for uncontrolled hypertension yes vs. no, all P 
0.03. Gender and years since the first diagnosis of diabetes were
not significant.
Discussion
Fluid retention and heart failure with
thiazolidinediones
The use of TZDs has been limited by the knowledge that these
agents can cause fluid retention and lead to the development of
HF.12 This has led to marketing contraindications in patients with
HF and to guidelines cautioning the use of these compounds in
some patients with pre-existing cardiovascular disease.4
We report here that rosiglitazone added to either metformin or
sulfonylurea was associated with a two-fold increase in the risk of
HF hospitalizations or death when compared with standard dual
therapy. These results, observed in a population of more than
4400 people with a mean follow-up of more than 5 years
confirm and extend previous observations. Unlike previous
studies, we used predefined criteria for HF based on the European
Society of Cardiology guidelines, and a specific CEC prospectively
adjudicated all HF endpoints. This process limited the risk of not
capturing or of misdiagnosing HF events, and the incidence of
HF observed in RECORD is likely to reflect the size of the
problem in patients treated with TZDs.
In particular, the magnitude of the excess risk observed here is
in line with data from a recent meta-analysis which reported an
overall excess risk of 72%, with no heterogeneity between piogli-
tazone and rosiglitazone.6
The mechanism of TZD-induced fluid retention and oedema
remains unclear. In vitro and animal studies suggest that the
PPARg agonists stimulate sodium re-absorption in the distal
nephron by up-regulating the expression and translocating the col-
lecting duct epithelial sodium channel.13– 16 By contrast, no direct
effect of TZDs on cardiac function or structure has been
reported.17
In people with pre-existing cardiac disease or HF, fluid reten-
tion and plasma volume expansion can induce HF decompensa-
tion. People with diabetes are prone to develop coronary
artery disease and diastolic dysfunction, and poor glycaemic
control is associated with increased incidence of HF.18,19 Thus,
TZD-induced fluid retention is therefore of particular concern
in this population at risk of developing HF: in clinical trials
which excluded people with a history of HF, TZDs induced a
small increase in HF episodes,20 whereas in the PROactive
study pioglitazone was associated with a 6% incidence of HF hos-
pitalizations over a follow-up of almost 3 years in people with
type 2 diabetes and macrovascular disease, half of these with a
previous myocardial infarction. The risk of HF episodes with
TZDs increases with the prevalence of the underlying cardiac
disease. This finding is confirmed in RECORD, although a min-
ority of participants had a history of prior documented IHD or
of a previous macrovascular event. In the subgroup which had
a previous IHD, the incidence of HF events was higher (4.4%)
than in people without previous IHD (2.4%) in the rosiglitazone
group. However, the same was true for the metformin/sulfony-
lurea control group (HF incidence with previous IHD 2.1%; inci-
dence without 1.1%) giving similar relative risk, rosiglitazone vs.
control (2.16 and 2.10) in the two subgroups. These findings
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Table 1 Outcome of patients with heart failure events
(fatal and non-fatal)
Rosiglitazone
(n 5 2220)
Control
(n5 2227)
Patients with HF events (fatal and
non-fatal)
61 29
First HF event fatal 4 0
Survived first HF event 57 29
All-cause death (%) 17 (30) 8 (28)
HF death 6 2
Other CV deatha 9 2
Other death 2 4
Further non-fatal HF event (%) 7 (12) 5 (17)
Other non-fatal CV event (%) 13 (23) 10 (34)
No other CV event (%) 26 (46) 15 (52)
Data are number of patients (per cent of those surviving first HF event). Note:
participants may experience multiple events (both HF and CV), so numbers in
each category will not sum to the number surviving the first HF event.
aOther CV death includes one fatal MI on same day as first HF hospitalization.
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Table 2 Relative risk for heart failure events in patients with and without prior ischaemic heart disease
Rosiglitazone Control Relative risk (95% CI) P-value for interaction
All 61/2220 (2.7) 29/2227 (1.3) –
Prior ischaemic heart disease 17/383 (4.4) 8/389 (2.1) 2.16 (0.94, 4.94)
No prior ischaemic heart disease 44/1837 (2.4) 21/1838 (1.1) 2.10 (1.25, 3.51) 1.00 (NS)
Data are patients with HF events/number of patients randomized and treated (%).
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must, however, be interpreted with caution, given the small size
of the population with prior IHD and therefore the small number
of events observed in this group.
Four baseline factors were independent predictors of HF in
addition to rosiglitazone treatment: elderly people, people with
increased body mass index, those with microalbuminuria or
overt proteinuria, and people with increased systolic blood
pressure were at a substantially increased risk of HF events.
Albumin/creatinine ratio is a recognized marker of diabetic
nephropathy, and interventions which reduce the development
or the progression of this complication have been associated
with a significant reduction in HF events.21,22 Of note, a history
of previous cardiovascular disease was not predictive in our
model, but the absolute risk of HF was increased in patients
with previous IHD. In another study, pioglitazone use, renal dys-
function, diuretic use, LDL cholesterol, previous myocardial
infarction, age, duration of diabetes, HbA1c, and body mass
index were identified as independent predictors of HF events.23
Most of these factors have been previously recognized as predic-
tors of HF in people with diabetes.24 Elderly patients with obesity
or increased body mass index or with proteinuria, renal
dysfunction, or hypertension should therefore be closely followed
for signs and symptoms suggestive of HF when treated with
TZDs.
Heart failure and cardiovascular
outcomes
It has been suggested that the increased event rate of HF with
TZDs is not associated with an increase in cardiovascular
mortality.6
In the PROactive study, the number of deaths from HF was
similar in the pioglitazone group (25) and in the placebo group
(22), and in patients reported to have a serious HF event, the sub-
sequent rate of death from any cause, myocardial infarction, or
stroke was lower in the pioglitazone group.5 The number of
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Table 3 Baseline characteristics of patients who
developed heart failure over time
Participants
with HF
adjudicated
event
(n5 90)
Participants
without HF
adjudicated
event
(n 5 4357)
Age (years) 63.8 (7.3) 58.3 (8.3)
Sex (male) 50 (55.6) 2244 (51.5)
Ischaemic heart disease 25 (27.8) 747 (17.1)
Stable angina 17 (18.9) 440 (10.1)
Myocardial infarction 5 (5.6) 213 (4.9)
Coronary angioplasty 5 (5.6) 129 (3.0)
Unstable angina 3 (3.3) 47 (1.1)
Stroke 7 (7.8) 101 (2.3)
Transient ischaemic attack 3 (3.3) 95 (2.2)
Peripheral arterial disease 12 (13.3) 398 (9.1)
Cerebrovascular disease 9 (10.0) 183 (4.2)
Heart failure 2 (2.2) 19 (0.4)
Hypertension 85 (94.4) 3478 (79.8)
Statins 13 (14.4) 810 (18.6)
Fibrates 3 (3.3) 246 (5.6)
Diuretics 33 (36.7) 883 (20.3)
Thiazide diuretics 25 (27.8) 748 (17.2)
Loop diuretics 8 (8.9) 135 (3.1)
b-Adrenergic blockers 35 (38.9) 964 (22.1)
ACE-inhibitors/A2R blockers 55 (61.1) 2038 (46.8)
Calcium-channel blockers 32 (35.6) 881 (20.2)
Nitrates 10 (11.1) 262 (6.0)
Antiplatelet agents 26 (28.9) 844 (19.4)
Current smoker 11 (12.2) 695 (16.0)
Previous smoker 30 (33.3) 1074 (24.6)
Microalbuminuria or proteinuriaa 41 (49) 810 (22)
Duration of diabetes (years) 7.5 (4.9) 7.1 (4.9)
Waist circumference (cm) 110.9 (13.2) 104.6 (11.7)
Weight (kg) 93.1 (17.8) 88.9 (16.0)
BMI (kg/m2) 33.5 (5.6) 31.4 (4.8)
HbA1c (%) 7.84 (0.69) 7.90 (0.70)
Blood pressure
sBP (mmHg) 148.7 (18.9) 138.6 (15.3)
dBP (mmHg) 84.5 (9.8) 82.9 (8.3)
Heart rate (bpm) 73.1 (9.7) 73.7 (8.6)
LDL cholesterol (mmol/L) 3.3 (0.9) 3.3 (0.9)
HDL cholesterol (mmol/L) 1.2 (0.3) 1.2 (0.3)
Haemoglobin (g/L) 141.5 (12.7) 141.7 (11.6)
Serum creatinine (mmol/L) 68.8 (18.0) 64.6 (17.6)
Uric acid (mmol/L) 327.0 (82.9) 297.4 (78.1)
Sodium (mmol/L) 140.4 (2.4) 140.1 (2.3)
Blood urea nitrogen (mmol/L) 6.2 (1.4) 5.7 (1.5)
Data are number (%) or mean (SD). HbA1c, haemoglobin A1c.
aMicroalbuminuria: ACR 2.5 to ,30.0 mg/mmol in males and ACR 3.5 to
,30.0 mg/mmol in females. Proteinuria: ACR 30.0 mg/mmol.
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Table 4 Significant baseline predictors of heart failure
risk by multivariable analysis
Variable HR 95% CI x2 P-value
Age (per 1-year increase) 1.10 (1.07–1.14) 39.71 ,0.001
Urinary albumin : creatinine
ratio (microalbuminuria/
proteinuria vs.
normoalbuninuria)
3.09 (2.01–4.77) 26.12 ,0.001
Body mass index (per 1 kg/
m2 increase)
1.11 (1.06–1.15) 23.94 ,0.001
Rosiglitazone assignment
(rosiglitazone vs. control)
2.33 (1.46–3.70) 12.74 ,0.001
Systolic blood pressure (per
1 mmHg increase)
1.02 (1.01–1.03) 9.18 0.002
Model based on n ¼ 3849 (86%) patients with n ¼ 84 (93%) HF events with
complete data on the four baseline characteristics identified as predictors (via
stepwise selection and 5% significance).
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patients with serious HF for whom the HF event resolved during
follow-up was also similar between treatment groups. In the
RECORD trial, the number of primary events (cardiovascular mor-
tality or cardiovascular hospitalization) was similar in the two treat-
ment groups, and there were somewhat fewer cardiovascular
deaths in the rosiglitazone group (60) than in the control group
(71).8 This was also true for specific causes of cardiovascular
death, including sudden cardiac death, myocardial infarction, or
stroke, and for all-cause deaths, but as with cardiovascular death,
the difference was not significant.8
By contrast, we observed an excess in HF deaths (10 vs. two),
including four fatal initial HF events in the rosiglitazone group.
Six additional patients surviving an initial HF event subsequently
experienced an HF death when compared with two in the
control group. We therefore cannot conclude that HF events
with rosiglitazone are all benign episodes of reversible fluid
retention.
The fatal and non-fatal HF event rate was higher in PROactive
than in RECORD. This is probably because all patients in PROac-
tive had prior macrovascular disease, including myocardial infarc-
tion in 47%.
The length of hospitalizations related to HF events was 10
days and was similar in both groups. This finding is consistent
with the observation of HF hospitalizations in the PROactive
study and with the average length of hospitalization for an HF
population in Europe.
More people in the rosiglitazone group experienced multiple
episodes of HF than in the control group. However, in survivors
of a first HF event, the number of people who experienced a
further HF event or a further other cardiovascular event was
similar in the two treatment groups.
The comparison of HF events in the two large outcome studies
with TZDs, RECORD and PROactive, is difficult due to differences
in design and inclusion criteria. Furthermore, the duration of
follow-up in PROactive was shorter than in RECORD (34.5 vs.
66 months), a factor which may have played a role in the long-term
assessment of events and outcome of a chronic condition such as
HF. Finally, it is noteworthy that HF was not a protocol-defined
centrally adjudicated event in PROactive.
Strengths and limitations
The detailed analysis of HF events in the RECORD trial provides
incremental information on the risk of developing this adverse
event in a broad clinically representative population of people
with type 2 diabetes exposed to rosiglitazone for a long period
of time and carefully followed-up. Heart failure is a potentially
‘soft’ endpoint in this population due to confounding disorders
such as obesity or non-cardiac peripheral oedema. The prospec-
tive adjudication of all hospitalizations or deaths by an endpoint
committee blinded to medications and using pre-specified criteria
based on the European Society of Cardiology guidelines limited the
risk of misdiagnosis of HF in our study.25 In particular, the diagnosis
of HF systematically required the documentation of cardiac
dysfunction and of HF medication changes in addition to the pres-
ence of signs and symptoms of HF.
There are some weaknesses in this secondary analysis: some-
what higher use of loop diuretics (4% by 5 years) in the rosigli-
tazone group may have attenuated the incidence of HF, although
we are unable to attribute the reason for investigator’s prescrip-
tion of these medications. The mean age of the population was
60 years, and we cannot extend our conclusions to the
elderly or the very elderly, a population at high risk of HF.
Owing to the limited number of HF events and of the non-
randomized nature of the decision to continue or discontinue
rosiglitazone after an event, we cannot draw any conclusion on
the risk of HF in patients experiencing an HF event and continuing
rosiglitazone.
Finally, we examined only HF hospitalizations or deaths. The
actual incidence of fluid retention cannot therefore be assessed
from our analysis, although the CEC examined all presumed cardi-
ovascular serious adverse events.
Conclusion
We found that HF events were twice as common in people with
type 2 diabetes and increased body mass index treated by rosigli-
tazone added to metformin or a sulfonylurea than in the conven-
tional dual-therapy group. A number of factors were identified as
predictors of HF in addition to treatment with rosiglitazone.
Elderly people, people with markedly increased body mass index,
people with microalbuminuria/proteinuria, and people with
increased systolic blood pressure are particularly at risk of HF
and should be offered close follow-up.
Finally, although rosiglitazone was not associated with increased
cardiovascular mortality or morbidity, an excess number of HF
deaths was observed. Overall, our findings support the guidelines
issued for the management of patients treated with TZDs in the
presence of HF. The development of HF in patients treated with
this compound should lead to discontinuation.
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Appendix 2. List of baseline
variables included in the predictive
modelling analysis
Demographics/diabetes history
Age (years)/gender
BMI (kg/m2)
Waist circumference (cm)
HbA1c (%)
Duration of diabetes (years)
Medical history
Previous smoker vs. non-smoker
Current smoker vs. non-smoker
Diagnosed hypertension
Peripheral vascular disease
Cerebrovascular disease
Myocardial infarction
Baseline medications
Nitrates
ACE-inhibitor/ARBs
Diuretics
Calcium-channel blockers
Beta-blockers
Anti-platelets
Statins
Haematology and chemistry
LDLc (mmol/L)
HDLc (mmol/L)
Heart rate (bpm)
Systolic BP (mmHg)
Diastolic BP (mmHg)
Haemoglobin (g/L)
Creatinine (mmol/L)
Urinary albumin/creatinine ratio (microalbuminuria/proteinuria vs.
normoalbuminuria)
Uric acid (mmol/L)
Sodium (mmol/L)
Blood urea nitrogen (mmol/L)
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